CaDAnCe-101
Phase 1/2 Recruiting
614 enrolled
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
Phase 2 Recruiting
28 enrolled
MK-1026-003
Phase 2 Recruiting
490 enrolled
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Phase 1 Recruiting
24 enrolled
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Phase 2 Recruiting
31 enrolled
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Recruiting
439 enrolled
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Phase 2 Recruiting
35 enrolled
GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL
Phase 1 Recruiting
45 enrolled
A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies
Phase 1 Recruiting
130 enrolled
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Phase NA Recruiting
200 enrolled
BRUIN-CLL-314
Phase 3 Recruiting
662 enrolled
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Phase 1/2 Recruiting
126 enrolled
Tissue Collection for Studies of Lymph Cancer
Recruiting
1,295 enrolled
Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols
Recruiting
500 enrolled
PIC1 Injection Therapy for Relapsed/Refractory B-NHL
Phase 1 Recruiting
18 enrolled
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Phase 1/2 Recruiting
940 enrolled 1 FDA
SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas
Phase 1/2 Recruiting
48 enrolled
CAPTUR
Phase 2 Recruiting
720 enrolled
PiNACLE-H2H
Phase 3 Recruiting
400 enrolled
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase 1/2 Recruiting
37 enrolled
EPCOREâ„¢FL-2
Phase 3 Recruiting
1,095 enrolled
ENABLE-2
Phase 2 Recruiting
60 enrolled
GRALE
Phase 1 Recruiting
136 enrolled
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Phase 2 Recruiting
100 enrolled
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Phase 4 Recruiting
787 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma
Phase 1 Recruiting
55 enrolled
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Phase 1/2 Recruiting
147 enrolled
Study of LYL314 in Aggressive Large B-Cell Lymphoma
Phase 1/2 Recruiting
270 enrolled
Lumi-NHL
Phase 1/2 Recruiting
91 enrolled
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Phase 1/2 Recruiting
100 enrolled
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Phase 1 Recruiting
121 enrolled
Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
132 enrolled
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
Phase 1 Recruiting
25 enrolled
PALS
Phase NA Recruiting
110 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Recruiting
30 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Recruiting
1,263 enrolled
TAPUR
Phase 2 Recruiting
4,200 enrolled
Study of SGR-1505 in Mature B-Cell Neoplasms
Phase 1 Recruiting
98 enrolled
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets
Phase 1 Recruiting
150 enrolled
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Phase 2 Recruiting
30 enrolled
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Phase 1/2 Recruiting
32 enrolled
NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
Phase 1 Recruiting
24 enrolled
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Recruiting
99,999 enrolled
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL
Phase 2 Recruiting
24 enrolled
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Phase 1 Recruiting
280 enrolled
SJFAMILY
Recruiting
1,500 enrolled
ACIT001/EXC002
Phase 1/2 Recruiting
63 enrolled